Preparation of vincristine sulfate-loaded poly (butylcyanoacrylate) nanoparticles modified with pluronic F127 and evaluation of their lymphatic tissue targeting

References

• Nune SK, Gunda P, Majeti BK, et al. Advances in lymphatic imaging and drug delivery. Adv Drug Deliv Rev 2001;63:876–85
   Google Scholar
• Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med 2002;8:751–5
   PubMed Web of Science ®Google Scholar
• Apostolidou E, Swords R, Alvarado Y, Giles FG. Treatment of acute lymphoblastic leukaemia: a new era. Drugs 2007;67:2153–71
   PubMed Web of Science ®Google Scholar
• Pulte D, Gondos A, Brenner H. Trends in survival after diagnosis with hematologic malignancy in adolescence or young adulthood in the United States, 1981–2005. Cancer 2009;115:4973–9
   PubMed Web of Science ®Google Scholar
• Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007;109:944–50
   PubMed Web of Science ®Google Scholar
• Yang F, Fu DL, Long J, Ni QX. Magnetic lymphatic targeting drug delivery system using carbon nanotubes. Med Hypotheses 2008;70:765–7
   PubMed Web of Science ®Google Scholar
• Fujiwara K, Watanabe T. Effects of hyperthermia, radiotherapy and thermoradiotherapy on tumor microvascular permeability. Acta Pathol Jpn 1990;40:79–84
   PubMedGoogle Scholar
• Chen J, Wang L, Yao Q, et al. Drug concentrations in axillary lymph nodes after lymphatic chemotherapy on patients with breast cancer. Breast Cancer Res 2004;6:474–7
   PubMed Web of Science ®Google Scholar
• Narvuzov SN, Zkbarov ET, Abduzhabborov SB, et al. Preliminary results of lymphatic chemotherapy in the treatment of rectal cancer. Klin Khir 2004;3:38–40
   PubMedGoogle Scholar
• Reddy GR, Bhojani MS, McConville P, et al. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res 2006;12:6677–86
   PubMed Web of Science ®Google Scholar
• Thomas PH, Joseph GA. Effective tumor targeting and enhanced anti-tumor effect of liposomes engrafted with peptides specific for tumor lymphatics and vasculature. Int J Pharm 2011;411:206–14
   PubMedGoogle Scholar
• Reddy ST, Rehor A, Schmoekel HG, et al. In vivo targeting of dendritic cells in lymph nodes with poly (propylene sulfide) nanoparticles. J Control Release 2006;112:26–34
   PubMed Web of Science ®Google Scholar
• Rowinsky E, Donhower RC. Antimicrotubule agents. In: Chabner BA, Longo DL, eds. Cancer chemotherapy and biotherapy. Philadelphia: Lippincott-Raven Publishers; 1996:263–75
   Google Scholar
• Barthomeuf C, Grassi J, Demeule M, et al. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin. Cancer Chemother Pharmacol 2005;56:173–81
   PubMed Web of Science ®Google Scholar
• Borst P, Zelcer N, van de Wetering K, Poolman B. On the putative co-transport of drugs by multidrug resistance proteins. FEBS Lett 2006;580:1085–93
   PubMed Web of Science ®Google Scholar
• Marinina J, Shenderova A, Mallery SR, Schwendeman SP. Stabilization of vinca alkaloids encapsulated in poly(lactide-co-glycolide) microspheres. Pharm Res 2000;17:677–83
   PubMed Web of Science ®Google Scholar
• Ariasa JL, Linares-Molineroa F, Gallardoa V, Delgadob AV. Study of carbonyl iron/poly(butylcyanoacrylate) (core/shell) particles as anticancer drug delivery systems Loading and release properties. Eur J Pharm Sci 2008;33:252–61
   PubMed Web of Science ®Google Scholar
• Soma CE, Dubernet C, Bentolila D, et al. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials 2000;21:1–7
   PubMed Web of Science ®Google Scholar
• Arias JL, Gallardo V, Ruiz MA, Delgado AV. Magnetite/poly (alkylcyanoacrylate) (core/shell) nanoparticles as 5-Fluorouracil delivery systems for active targeting. Eur J Pharm Biopharm 2008;69:54–63
   PubMed Web of Science ®Google Scholar
• Arias JL, Gallardo V, Ruiz MA, Delgado AV. Ftorafur loading and controlled release from poly(ethyl-2-cyanoacrylate) and poly(butylcyanoacrylate) nanospheres. Int J Pharm 2007;337:282–90
   PubMed Web of Science ®Google Scholar
• Vauthier C, Dubernet C, Chauvierre C, et al. Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J Control Release 2003;93:151–60
   PubMed Web of Science ®Google Scholar
• Nemati F, Dubernet C, Fessi H, et al. Reversion of multidrug resistance using nanoparticles in vitro: influence of the nature of the polymer. Int J Pharm 1996;138:237–46
   Web of Science ®Google Scholar
• Ambruosi A, Khalansky AS, Yamamoto H, et al. Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. J Drug Target 2006;14:97–105
   PubMed Web of Science ®Google Scholar
• Friesea A, Seillera E, Quacka G, et al. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur J Pharm Biopharm 2000;49:103–9
   PubMed Web of Science ®Google Scholar
• Zhang W, Shi Y, Chen Y, et al. Enhanced antitumor efficacy by Paclitaxel-loaded Pluronic P123/F127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance. Eur J Pharm Biopharm 2010;75:341–53
   PubMed Web of Science ®Google Scholar
• Tan R, Liu Y, Feng N, Zhao J. Preparation and in vitro release characteristics of vincristine sulphate loaded poly (butylcyanoacrylate) nanoparticles. Zhongguo Zhong Yao Za Zhi (in Chinese) 2011;36:1431–5
   PubMedGoogle Scholar
• Ling G, Zhang P, Zhang W, et al. Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition. J Control Release 2010;148:241–8
   PubMed Web of Science ®Google Scholar
• Na JH, Lee SY, Lee S, et al. Effect of the stability and deformability of self-assembled glycol chitosan nanoparticles on tumor-targeting efficiency. J Control Release 2012;163:2–9
   PubMed Web of Science ®Google Scholar
• Gu J, Song ZP, Gui DM, et al. Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in lymphoma nude mice by heme oxygenase-1 induction. Cardiovasc Toxicol 2012;12:341–9
   PubMed Web of Science ®Google Scholar
• Salgado Oloris SC, Dagli NL, Guerra JL. Effect of β-carotene on the development of the solid Ehrlichtumor in mice. Life Sci 2002;71:717–24
   PubMed Web of Science ®Google Scholar
• Kim WJ, Yockman JW, Jeong JH, et al. Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice. J Control Release 2006;114:381–8
   PubMed Web of Science ®Google Scholar
• Page ME, Pinto-Alphandary H, Chachaty E, et al. Entrapment of colistin into polyhexylcyanoacrylate nanoparticles: preparation, drug release and tissue distribution in mice. STP Pharm Sci 1996;6:298–301
   Google Scholar
• Costa P, Lobo JMS. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001;13:123–33
   PubMed Web of Science ®Google Scholar
• Hee J Lee, Byung-N Ahn, Woo H Paik, et al. Inverse targeting of reticuloendothelial system-rich organs after intravenous administration of adriamycin-loaded neutral proliposomes containing poloxamer 407 to rats. Int J Pharm 1996;131:91–6
   Google Scholar
• Shin SB, Cho HY, Kim DD, et al. Preparation and evaluation of tacrolimus-loaded nanoparticles for lymphatic delivery. Eur J Pharm Biopharm 2010;74:164–71
   PubMed Web of Science ®Google Scholar
• Moghimi SM. Modulation of lymphatic distribution of subcutaneously injected poloxamer 407-coated nanospheres: the effect of the ethylene oxide chain configuration. FEBS Lett 2003;540:241–4
   PubMed Web of Science ®Google Scholar
• Zhang L, Gao H, Chen L, et al. Tumor targeting of vincristine by mBAFF-modified PEG liposomes in B lymphoma cells. Cancer Lett 2008;269:26–36
   PubMed Web of Science ®Google Scholar
• Davis T, Farag SS. Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine. Int J Nanomedicine 2013;8:3479–88
   PubMed Web of Science ®Google Scholar
• Thakkar HP, Baser AK, Parmar MP, et al. Vincristine-sulphate-loaded liposome-templated calcium phosphate nanoshell as potential tumor-targeting delivery system. J Liposome Res 2012;22:139–47
   PubMed Web of Science ®Google Scholar
• Güthlein F, Burger AM, Brandl M, et al. Pharmacokinetics and antitumor activity of vincristine entrapped in vesicular phospholipid gels. Anticancer Drugs 2002;13:797–805
   PubMed Web of Science ®Google Scholar
• Junping W, Takayama K, Nagai T, Maitani Y. Pharmacokinetics and antitumor effects of vincristine carried by microemulsions composed of PEG-lipid, oleic acid, vitamin E and cholesterol. Int J Pharm 2003;251:13–21
   PubMedGoogle Scholar
• Wang C, Zhao M, Liu YR, et al. Suppression of colorectal cancer subcutaneous xenograft and experimental lung metastasis using nanoparticle-mediated drug delivery to tumor neovasculature. Biomaterials 2014;35:1215–26
   PubMed Web of Science ®Google Scholar
• Chen J, Li S, Shen Q. Folic acid and cell-penetrating peptide conjugated PLGA-PEG bifunctional nanoparticles for vincristine sulfate delivery. Eur J Pharm Sci 2012;47:430–43
   PubMed Web of Science ®Google Scholar
• Zhang P, Ling G, Sun J, et al. Multifunctional nanoassemblies for vincristine sulfate delivery to overcome multidrug resistance by escaping P-glycoprotein mediated efflux. Biomaterials 2011;32:5524–33
   PubMed Web of Science ®Google Scholar